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Effective prevention of human cancer with vaccines against viruses, such as HBV and
HPV, raises the question whether also non-virus related tumors could be prevented with
immunological means. Studies in HER-2-transgenic mice showed that powerful anti-HER-2
vaccines, could almost completely prevent the onset of mammary carcinoma. Protective
immune responses were orchestrated by T cells and their cytokines, and effected by anti-
bodies against HER-2 gene product p185. Analogous findings were reported in a variety of
other cancer immunoprevention systems, thus leading to the definition of oncoantigens,
optimal target antigens that are causally involved in carcinogenesis and cancer progres-
sion. Prophylactic HER-2 vaccines were also effective in preventing metastasis outgrowth,
indicating that concepts and approaches developed for cancer immunoprevention could
prove fruitful in cancer immunotherapy as well. The availability of cancer-prone mice carry-
ing a human HER-2 transgene is now fostering the design of novel vaccines against human
p185. A further bridge toward human cancer was recently provided by novel immunode-
ficient models, like Rag2−/−;Il2rg−/− mice, which are permissive for metastatic spread of
human HER-2+ cancer cells and can be engrafted with a functional human immune sys-
tem, allowing for the first time the study of vaccines against oncoantigens to elicit human
immune responses against human cancer cells in vivo.
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HER-2 IS A CLASS I ONCOANTIGEN
HER-2 is at the same time an oncogene and an antigen. HER-2-
addicted cancer cells cannot easily give rise to antigen-loss variants
to escape immune attacks (Nanni et al., 2000).
Furthermore, the HER-2 gene product, p185, is a surface pro-
tein, hence it is recognized and bound by antibodies. It is also
recognized by T cells, as a result of antigen processing and major
histocompatibility complex (MHC) presentation. The persistence
of recognition by antibodies in the presence of MHC loss makes
p185 impervious to the total loss of immune recognition that
affects intracellular tumor antigens.
These properties make HER-2 a class I oncoantigen. Oncoanti-
gens are defined as those tumor antigens that have a causal role in
tumor growth and progression (Lollini et al., 2006). Recently, the
oncoantigens were divided in three classes, according to surface
(class I), extracellular (class II), or intracellular (class III) protein
localization (Lollini et al., 2011).
More than half a century of intensive immunological research
has led to the accumulation of a database of hundreds of mol-
ecules defined as tumor antigens. However, their suitability as
targets of cancer preventive or therapeutic approaches is uneven.
The definition of oncoantigens was a first step to define priorities
in the galaxy of tumor antigens, first between oncoantigens and
non-oncoantigens, then among oncoantigen classes. The readers
interested in a more clinically oriented attempt at tumor antigen
prioritization are referred to a recent collective work of tumor
immunologists (Cheever et al., 2009). It is interesting to note
that two properties taken into account were “oncogenicity” and
“cellular location of antigen,” that is the defining properties of
class I oncoantigens.
In summary, HER-2 is endowed with relevant immunological
properties that many other tumor antigens lack, making it an ideal
target antigen for long-term cancer immunoprevention.
CANCER IMMUNOPREVENTION
The immune system actively prevents tumor onset, as is clearly
demonstrated by the huge increase in cancer development in
genetically modified immunodeficient mice. The same happens in
immunodeficient humans, who are mostly prone to viral tumors.
Altogether, it can be said that the immune system defends the host
both from pathogens and from tumors, and that any decrease in
the immune defenses exposes the host to the risk of infections
and neoplasms (Dunn et al., 2004; Finn, 2008; Cavallo et al., 2011;
Hanahan and Weinberg, 2011).
Just as immunity from microbes is not 100% efficient, thus
leaving the host exposed to the risk of a variety of infections,
immunity from tumors is not perfect, and the risk of carcinogene-
sis is always present. This is especially true in the aging hosts, owing
to a long history of potentially tumorigenic DNA mutations and
to the age-related impairment of immune defenses.
A further parallel between infectious and tumor immunity
is the possibility to enhance the immunity of healthy individ-
uals with vaccines. In the field of cancer preventive vaccines,
we have now two distinct stages of development. The vaccines
against oncogenic viruses are already implemented at the pop-
ulation level, to immunize healthy individuals against hepatitis
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B virus or papillomaviruses (Schiller et al., 2008; Chang et al.,
2009). However, most tumors (>80%) are not caused by infectious
agents, and no prophylactic vaccine exists to immunize humans
against such tumors. We will discuss here the preclinical develop-
ment of vaccines to prevent carcinogenesis in HER-2-transgenic
mice, showing that non-infectious tumors could be prevented with
immunological means.
MOUSE MODELS FOR ANTI-HER-2 VACCINES IN CANCER
IMMUNOPREVENTION AND IMMUNOTHERAPY
The earliest studies of cancer immunoprevention were done in
HER-2-transgenic mice harboring an activated (i.e., mutant) ver-
sion of the rat oncogene, which causes a very aggressive mammary
carcinogenesis. In these mice, the first carcinoma appears at 4–
5 months of age, and is rapidly followed by other primary tumors
in all ten mammary glands; most animals develop also distant
metastases (Boggio et al., 1998).
Human cancer is often caused by a combination of mutations
in oncogenes and tumor suppressor genes. To model this situ-
ation, we then applied cancer immunoprevention to a bigenic
mouse model that combines HER-2 activation and heterozygous
p53 knockout. Female mice develop mammary and salivary car-
cinomas (Croci et al., 2004). It should be noted that the null p53
allele in itself does not provide immunological targets, therefore,
in these bigenic mice, as in HER-2 transgenic mice, p185 is the
target antigen.
More recently, cancer-prone transgenic mice lines carrying a
human HER-2 transgene were also established (Finkle et al., 2004).
In a sense, these mice validate previous models, because mam-
mary carcinogenesis resembles that of mice carrying the rat HER-2
transgene (Guy et al., 1992). The added value of human HER-2
transgenic mice stems from two types of specific application. They
can be used for preclinical testing of therapeutic agents against
human p185, for example monoclonal antibodies (Finkle et al.,
2004) that are not cross-reactive with rat HER-2. A more recent
application of human HER-2 expression in transgenic mice was the
establishment of mice carrying HER-2 variants found in patients,
such as the Delta16 isoform (Castiglioni et al., 2006; Marchini
et al., 2011), thus allowing the study of their carcinogenicity and
the direct comparison between wild-type and variant or mutant
forms of the HER-2 oncogene.
The major clinical issue of HER-2+ human breast cancer is
the metastatic spread to distant organs, including the lungs, the
bones, the brain, and various abdominal viscera. The study of
HER-2+ cancer dissemination has been hindered by the notorious
metastatic inefficiency of human HER-2+ breast cancer cell lines
in immunodeficient mouse models, such as athymic nude mice.
Most studies used HER-2-negative cell lines transfected with the
HER-2 gene under the control of a constitutive promoter, how-
ever it is questionable whether forced expression of HER-2 in a
HER-2-negative cell provides a realistic target for preclinical cancer
therapy.
We have recently found a solution to this long-standing prob-
lem, thanks to the use of newer immunodeficient mouse hosts.
Double knockout BALB/c Rag2−/−;Il2rg−/− (BRG) mice lack T,
B, and natural killer (NK) cells, and are popular hosts for recon-
stitution with normal human immune cells. Some years ago we
found that BRG mice are superior to nude mice for studies of
metastatic dissemination of human sarcomas (Nanni et al., 2010),
therefore we compared the metastatic capacity of human HER-2+
breast cancer cell lines MDA-MB-453 and BT-474 in nude and in
BRG mice (Nanni et al., 2012).
We found that, unlike nude mice, BRG mice allow a multiorgan
metastatic spread that closely resembles the dissemination patterns
of breast cancer in patients. Metastases were found in the brain,
the lungs, the liver, the kidneys and adrenals, the ovaries, the bones,
and the bone marrow, and in various other anatomical locations
(Figure 1). Interestingly, overlapping patterns of metastatic dis-
semination were observed both after intravenous administration
of cancer cells and from local tumors growing in the mammary
fat pad or subcutaneously (Nanni et al., 2012).
In the past, the low metastatic potential of malignant human
cancers in immunodeficient mice was attributed to xenogeneic
incompatibilities between human and murine cognate molecules
controlling the metastatic process. Our results in BRG mice clearly
demonstrate that, in the case of HER-2+ carcinomas, the major
obstacle to metastatic spread was the residual immune response of
nude mice, in particular NK activity, and that the full metastatic
potential of human cancer can be expressed in BRG mice. This new
model offers excellent opportunities for the preclinical testing of
antimetastatic drugs. As a first example, we found that BKM120, a
PI3K inhibitor that penetrates the blood-brain barrier, effectively
inhibited brain metastases of HER-2+ breast cancer (Nanni et al.,
2012).
Human hematopoietic stem cells implanted in BRG mice give
rise to a functional human immune system, and reconstituted
mice can be used for studies of lymphopoiesis and to analyze spe-
cific human immune responses (Brehm et al., 2010; Rongvaux
et al., 2013). In general, such studies reveal suboptimal human
responses, nonetheless this is the first in vivo model system allow-
ing the investigation of human immune responses without the
human body.
THE TRIPLEX VACCINE, OR HOW TO INCREASE THE
IMMUNOGENICITY OF CANCER CELLS FOR CANCER
IMMUNOPREVENTION
Our first attempt at cancer immunoprevention in HER-2 trans-
genic mice was based on the systemic administration of recombi-
nant interleukin 12 (IL-12), a key cytokine of antigen presentation,
that also stimulates NK activity (Boggio et al., 1998). The IL-
12 treatment significantly delayed tumor onset, however all mice
eventually succumbed to progressive mammary carcinomas. To
improve the efficacy of cancer immunoprevention, we decided to
switch from a non-antigen specific cytokine to antigen-specific
cell-based vaccines.
The major problem of vaccines made of tumor cells is that, in
most instances, the immunogenicity of unmodified tumor cells
is insufficient to elicit protective immune responses. The his-
tory of cell-based cancer vaccines is mostly the history of the
approaches and technologies used to increase immunogenicity.
Early attempts, based on physical treatments (e.g., heat or UV
radiation), chemical modifications, or infections with viruses had
limited success (Kobayashi, 1986). A major impulse to this field
came from the adoption of gene transduction, to obtain genetically
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FIGURE 1 | Multiorgan metastasis of HER-2+ human breast cancer in a
BRG mouse. The intramammary implant of EGFP-transduced MDA-MB-453
cells produced a local tumor which in turn gave rise to multiple metastases in
the bones (mandible and femur, left panel ), the ovary (left panel ), the lungs
(center panel ), the paravertebral lymph nodes (center panel ), and the brain
(right panel ). Left panel, ventral view; center panel, ventral view after removal
of the rib cage and abdominal viscera; left panel, dorsal view after partial
removal of the brain, to reveal a large underlying metastasis.
modified tumor cells expressing defined immunogenic stimuli.
The use of standardized recipient cell lines, such as the TS/A mam-
mary adenocarcinoma, allowed meaningful comparisons between
promising candidate genes, in particular those encoding cytokines
(Allione et al., 1994; Musiani et al., 1997). We showed that allo-
geneic class I MHC genes elicited strong polyclonal T cell activa-
tion that could further increase the immunogenicity of cytokine
gene-transduced tumor cells (Nanni et al., 1996).
Our previous experience with recombinant cell vaccines for
cancer therapy led to the design of the Triplex vaccine for the
immunoprevention of mammary carcinoma in HER-2 transgenic
mice. Triplex vaccines combine the p185 target antigen with two
powerful non-antigen specific stimuli, IL-12 and allogeneic class I
MHC molecules. The first implementation of the Triplex con-
cept combined vaccinations with HER-2-transgenic mammary
carcinoma cells expressing allogeneic class I MHC molecules and
systemic administrations of recombinant mouse IL-12 (Nanni
et al., 2001). The same cells were subsequently transduced with
IL-12 genes, to obtain local IL-12 release, thus avoiding systemic
cytokine administrations (De Giovanni et al., 2004). Both for-
mulations of the Triplex vaccine yielded positive results, that are
discussed together in the following sections.
IMMUNOPREVENTION OF MAMMARY CARCINOMA IN
HER-2 TRANSGENIC MICE
Vaccination of HER-2 transgenic BALB-NeuT mice with the
Triplex vaccines yielded a strong protection from mammary carci-
noma onset. All vaccinated mice were still tumor-free at 1 year of
age, more than 6 months after all non-vaccinated mice developed
progressive carcinomas (Nanni et al., 2001; De Giovanni et al.,
2004). The histological and molecular study of mammary glands
revealed that, at 1 year of age, vaccinated mice only had hyperplas-
tic lesions similar to those of young mice. In practice, vaccinations
had “frozen” progression at a very early stage, as vaccinated mice
were also devoid of in situ carcinomas (Nanni et al., 2001; Astolfi
et al., 2005).
Tumor progression in HER-2-transgenic mice is obviously
accompanied by a very high expression of p185 in the mammary
epithelium. To our surprise, mammary glands of vaccinated mice
expressed very little p185. In practice, the vaccination inhibited
the constitutive expression of the activated oncogene in the target
tissue (Nanni et al., 2001; De Giovanni et al., 2004).
A complex and powerful vaccine, like the Triplex, entails a large
number of experimental variables, in terms of vaccine compo-
nents and vaccination schedules, therefore we undertook a series
of studies to define the relevant components. The vaccination of
mice with single or paired components of the vaccine prolonged
the latency of mammary carcinomas, but in all cases it failed to
keep mice completely free from tumors for 6 months or more,
thus demonstrating that the Triplex was the minimal combination
affording full cancer prevention for at least a year (Palladini et al.,
2010). The use of short, or less intense vaccination schedules led to
similar conclusions. In all cases tumor-free survival was reduced
with respect to the chronic vaccination schedule (Palladini et al.,
2010).
The prophylactic HER-2 vaccines were also effective in prevent-
ing metastasis outgrowth, thus indicating that the concepts and
the approaches developed for cancer immunoprevention could be
effective also in cancer immunotherapy (Nanni et al., 2007).
PROTECTIVE IMMUNE MECHANISMS ELICITED BY THE
TRIPLEX VACCINE
We did not find evidence of strong cytotoxic T cell responses in
vaccinated mice. Major long-term effects of vaccination were the
induction of T cell cytokines, in particular IFN-gamma, and of
antibodies against p185 (Nanni et al., 2004).
To dissect more precisely the protective mechanisms,we crossed
BALB-NeuT transgenic mice with knockout mice deficient in
IFN-gamma or antibody production. In both cases the Triplex
vaccine became ineffective, thus indicating that both IFN-gamma
and antibodies were essential components of the protection from
mammary carcinogenesis. Interestingly, IFN-gamma deficiency


























































Lollini et al. Preclinical HER-2 vaccines
did not impair IgG1 responses to the vaccine, but abolished
the production of IG2a, IgG2b, and IgG3, thus indicating that
cytotoxic “Th1” immunoglobulin isotypes were the mediators of
tumor prevention. In antibody-deficient mice, it was found that
IFN-gamma was released in response to the vaccine. This shows
that, without antibodies, IFN-gamma does not prevent tumor
growth, therefore the key role of Triplex-induced IFN-gamma
in this system was to induce the isotypic switch to Th1-type
immunoglobulins (Nanni et al., 2004).
The fundamental role of antibodies in tumor prevention
allowed us to monitor the protective immune responses during
long-term vaccination studies. We found that the kinetics of anti-
bodies elicited by Triplex vaccines predicted, several months in
advance, the long-term tumor-free survival of mice. The two major
variables related to tumor prevention were a rapid induction of
high-titer specific antibodies and a long-term maintenance of the
antibody plateau. Any vaccination schedule failing to attain either
target inevitably resulted in tumor onset (Palladini et al., 2010).
DIFFERENT VACCINES FOR THE IMMUNOPREVENTION OF
MAMMARY CARCINOMA IN HER-2 TRANSGENIC MICE
The prevention of mammary carcinoma in HER-2 transgenic mice
was obtained by many Laboratories, using a variety of immuno-
logical approaches, such as cell vaccines (Reilly et al., 2000; Nanni
et al., 2001; Murata et al., 2006; Masuelli et al., 2007), exosomes
(Hartman et al., 2011), protein or peptide vaccines (Esserman
et al., 1999; Dakappagari et al., 2000; Vertuani et al., 2004; Gritza-
pis et al., 2010; Marzocchella et al., 2011; Uram et al., 2011), DNA
and viral vaccines (Amici et al., 1998; Pupa et al., 2005; Tegerstedt
et al., 2005; Jacob et al., 2006, 2009, 2010; Whittington et al., 2009;
Quaglino et al., 2010), and dendritic cell vaccines (Sakai et al., 2004;
Nabekura et al., 2008; Wei et al., 2009; Steel et al., 2010; Landuzzi
et al., 2011; Wang et al., 2012). These results, which we recently
reviewed in detail (Lollini et al., 2011), indicate that effective
immunoprevention of HER-2-driven mammary carcinogenesis
can be obtained with different vaccine technologies.
IMMUNOPREVENTION OF A POLYGENIC CANCER
SYNDROME
The Triplex vaccine was highly effective in preventing carcinogen-
esis also in the HER-2 transgenic, p53 hemizygous mice. Inter-
estingly, the tumors of non-vaccinated mice invariably lacked
the wild-type p53 allele and expressed HER-2, whereas the cor-
responding tissues of vaccinated mice were heterozygous, and
showed a low expression of HER-2. The results suggest that, in
this system, HER-2 hyperactivity enhanced the risk of p53 loss,
and that the vaccine-induced HER-2 suppression prevented also
the occurrence of further oncogenic events affecting p53 (Croci
et al., 2004).
In HER-2 transgenic BALB-NeuT mice, different Laborato-
ries have produced impressive immunopreventive results using
DNA vaccines against HER-2 (Rovero et al., 2000; Pupa et al.,
2001; Quaglino et al., 2004; Jacob et al., 2006; Gallo et al., 2007;
Cho et al., 2008). We exploited their experience to design a DNA
vaccine based on the Triplex concept, that combined plasmids
encoding HER-2 extracellular domain, IL-12, and a MHC gene
allogeneic with respect to the host (De Giovanni et al., 2009). A
direct comparison showed that both vaccine designs were equally
effective in preventing tumor onset, with some differences in the
elicited immune mechanisms. From a vaccinological perspective,
the overall conclusion was that the DNA vaccine, being molecu-
larly defined and requiring a lower number of administrations, had
a higher translational potential than the cell vaccine (De Giovanni
et al., 2009).
In addition to the bigenic mice discussed here, the concept of
cancer immunoprevention was applied in recent years to many dif-
ferent mouse models of cancer risk. We have recently reviewed the
subject, which goes beyond the present focus on HER-2, therefore
we will not duplicate here the extensive list of references (Lollini
et al., 2011). Cancer immunoprevention appears to be generally
applicable to the prevention of diverse tumor types, caused by
a wide range of cancer genes, using a great variety of effective
immunological approaches.
PRECLINICAL VACCINES AGAINST HUMAN HER-2
The results discussed above were obtained in mice carrying rat
HER-2 transgenes. More recently, we found that cell and DNA vac-
cines against human HER-2, similar in design to those described
above, were effective in preventing mammary carcinoma onset
in human HER-2 transgenic mice (De Giovanni, manuscript
in preparation). The efficacy of anti-human HER-2 vaccines in
immunocompetent, human HER-2 transgenic mice shows that
these models can be useful in the translation of vaccines from
preclinical to clinical situations.
A further step in translational studies is the use of “human-
ized”mice, i.e., immunodeficient mice reconstituted with a human
immune system, to investigate human, instead of mouse, immune
responses against HER-2.
We studied the induction of human anti-human HER-2
immune responses in BRG mice reconstituted at birth with human
cord blood CD34+ cells (De Giovanni et al., 2012). Young recon-
stituted mice received a vaccine designed according to the Triplex
concept, consisting of HER-2+ SK-OV-3 cells and human IL-12.
No attempt was made to match the MHC of donor CD34+ cells
with that of vaccine/tumor cells, therefore the cellular component
of the vaccine was xenogeneic in relation to the mouse and allo-
geneic relative to the reconstituted immune system. Immunized
mice were then repeatedly bled to study serological responses, and
finally challenged with live SK-OV-3 cells to verify protection.
We found that indeed vaccinated mice were partially pro-
tected, in particular from metastases. Obviously, the protection
could be attributed, in part, to the allogeneic components of the
human immune response. However, serological studies revealed
the induction of human antibodies against human p185, thus
demonstrating that the vaccine was effective in eliciting a specific
human immune reaction resembling those previously obtained in
rodent systems (De Giovanni et al., 2012).
TRANSLATIONAL DEVELOPMENTS
The translation of immunoprevention to HER-2-positive human
breast tumors would be a stimulating perspective. Novel strategies
to prevent the development of invasive breast cancer are highly
desirable for women at risk. For a review of preventive approaches
based on HER-targeted drugs or passive immunoprevention, i.e.,
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monoclonal antibodies, see (Howe and Brown, 2011). Immuno-
prevention of breast cancer could be applied to women at high
risk of invasive carcinoma, in particular to those with preneo-
plastic or early neoplastic conditions, such as atypical hyperplasia
or carcinoma in situ. It should be noted that the proportion of
HER-2-positive ductal carcinomas in situ (DCIS) is significantly
higher than that of more advanced cases (Muggerud et al., 2010;
Zhang et al., 2012). Neo-adjuvant clinical trials of vaccination with
HER-2-pulsed dendritic cells have been recently reported (Sharma
et al., 2012), thus suggesting that HER-2 vaccines could be applied
to HER-2-positive DCIS.
The prevention of HER-2+ metastasis development using
the Triplex vaccine (Nanni et al., 2007) indicated that effective
anti-HER-2 vaccines could be included in adjuvant therapy of
HER-2+ breast cancer, possibly as a strategy to maintain a long-
term antibody response to p185 after cessation of the monoclonal
antibody regimens.
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